Moderna Inc said on Thursday it has completed enrolling 30,000 participants in a late-stage study testing its experimental coronavirus vaccine.
Over 25,650 participants have so far received their second shot of the vaccine candidate, mRNA-1273, the company said.
Moderna said its study includes more than 11,000 participants from minority communities in the U.S., representing 37% of the study population.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Shounak Dasgupta) ((manojna.kalyani@thomsonreuters.com; +91 8061822700))
